BMS-193885

BMS-193885 is a potent, selective, and competitive small molecule antagonist of the neuropeptide Y1 (NPY Y1) receptor, originally developed by Bristol Myers Squibb. It exhibits high affinity for the human Y1 receptor (Ki of 3.3 nM) with significant selectivity over other NPY receptor subtypes such as Y2, Y4, and Y5. Although the compound is brain-penetrant and demonstrated the ability to reduce food intake and body weight in animal models of obesity through central Y1 receptor inhibition, it lacks oral bioavailability. Consequently, BMS-193885 has primarily served as a pharmacological research tool and has not advanced into human clinical trials.

Other names

BMS-193885 L-Lactic acidBMS193885 L-Lactic acidBMS 193885 L-Lactic acidBMS-193885 lactateBMS193885 lactateBMS 193885 lactate